氯氮平耐药精神分裂症的国际研究议程
本文为Lancet Psychiatry的健康政策文章,讨论氯氮平耐药精神分裂症(clozapine-resistant schizophrenia)的全球挑战,回顾氯氮平指南、诊断检测与治疗选择,并提出未来研究方向,包括创新疾病分类学现场试验、转化方法、流行病学研究和干预性研究,同时指出中低收入国家在研究中的代表性不足。
要点
- 约三分之一精神分裂症患者出现治疗抵抗症状,氯氮平耐药是重大未满足需求。
- 文章提出四类未来研究方向:疾病分类学现场试验、转化方法、流行病学研究和干预性研究。
- 中低收入国家在氯氮平耐药精神分裂症研究中代表性不足,需加强全球代表性。
核心结论
- 氯氮平耐药精神分裂症是精神病学中关键且未满足的需求,需通过跨国研究议程改善患者功能结局与生活质量。
研究设计与样本
- 本文为健康政策类文章,讨论氯氮平耐药精神分裂症的挑战并回顾相关指南、诊断检测与治疗选择。
- 文章提出未来研究方向,分为疾病分类学现场试验、转化方法、流行病学研究和干预性研究四类。
主要发现
- 约三分之一精神分裂症患者出现治疗抵抗症状,与生活质量显著下降相关。
- 目前缺乏对氯氮平耐药精神分裂症早期识别、诊断和管理研究途径的全面概述。
- 中低收入国家在氯氮平耐药精神分裂症研究中代表性不足。
临床怎么用
- 临床应关注精神分裂症患者的治疗抵抗症状,并认识到氯氮平耐药是重大未满足需求。
- 未来研究可参考文章提出的疾病分类学、转化、流行病学和干预性研究方向。
- 需关注中低收入国家患者的全球代表性,以改善氯氮平耐药精神分裂症的功能结局和生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.
引用
- Luykx JJ, Gonzalez-Diaz JM, Guu TW, et al. An international research agenda for clozapine-resistant schizophrenia. Lancet Psychiatry. 2023. PMID: 37329895. doi:10.1016/S2215-0366(23)00109-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。